$Aligos Therapeutics, Inc.(ALGS)$$Gilead Sciences(GILD)$$Arbutus Biopharma(ABUS)$ 🧪 Clinical conviction with ALG-000184 I’m fully convinced $ALGS (Aligos Therapeutics) is one of the most misunderstood small-cap biotech setups in the market. I’ve held this position for a long time because of my personal conviction in their science and its potential impact on someone I care about who struggles with liver disease. I’m confident Phase 2 B-SUPREME is the core catalyst. With regulatory approvals across multiple countries, ~200 patients enrolled, and Phase 1 data showing significant HBV DNA reductions after 96 weeks, this program has durability and credibility. It’s n
$Aligos Therapeutics, Inc.(ALGS)$🔺🅱️ṳ̈l̤̈l̤̈ï̤s̤̈ḧ̤ 📈 Performance Analysis, P&L Community Share for 10 Tiger Coins, +18.58% in Just 4 Days! 🇦🇺🌊🏔️ While exploring Tasmania’s scenic vistas, I have been actively trading, keeping a close eye on Aligos Therapeutics, Inc. ($ALGS). Over just 4 trading days, ALGS has delivered an 18.58% gain, moving from $20.95 to $23.70. This trade is a case study in fundamental strength aligning with sector momentum, and I am holding for further upside. Key Catalysts Behind This Investment: 1️⃣ Institutional Capital Infusion – Aligos secured a $105 million private placement, extending its R&D cash runway and reinforcing investor confidence in its clinical pipeline. 2️⃣ Sector Rotation into Biotech – Market
$Aligos Therapeutics, Inc.(ALGS)$ ☕️🇦🇺🚀🌞 From +0.44% to +12.35%: Morning Trades and Triumphs with ALGS! 🌞🇦🇺🦘🚀 Good morning from Hobart! As I sip my freshly brewed ☕️ coffee, I’m joined by some delightful garden companions, Tasmanian pademelons. These charming marsupials, with their soft dark brown fur and reddish bellies, are a common sight here, especially during the early hours. Yesterday, while enjoying this serene Tasmanian morning, I shared my position in Aligos Therapeutics ($ALGS), which was at +0.44%, with a price of $21.04. Fast forward 24 hours, and ALGS has soared to $23.54, elevating my unrealised P&L to an impressive +12.35%! 📈☕ Trading amidst Tasmania’s tranquil environment, accompanied by the gentle presence of pademelons, adds
$Aligos Therapeutics, Inc.(ALGS)$ 🚀🔬🚀📈🅱️ U͎ L͎ L͎ I͎ S͎ H͎ 🚀🔬🚀 🚀🔬🔥 $ALGS, Biotech Breakout with Institutional Backing and Major Upside! 💡🔬📈 🌟 Picture this: Yesterday, I found myself immersed in the Museum of Old and New Art (MONA) in Tasmania 🇳🇿🦘, captivated by some of the most provocative and unconventional works of art I’ve ever encountered. 🎨🖼️ At the same time, I was actively trading $ALGS, seamlessly merging the frontiers of biotech innovation with the avant-garde essence of contemporary art. 🔬✨ After all, why not balance high finance with high culture? 😎📊 In between soaking up MONA’s eccentric vibes and indulging in ocean-fresh oysters, I opened positions in $ALGS on 13Feb24 at $20.95. The stock has already increased 0.44 % above my en
$Aligos Therapeutics, Inc.(ALGS)$ 🚀🚀📈🅱️ U͎ L͎ L͎ I͎ S͎ H͎ 🚀🚀 Profits piling up like a well executed Fibonacci sequence today 💰📈 Another 💨 💨💨 quick 2.20% gain on ALGS in a short term swing, posted about it on 29Jan25 and the setup played out beautifully. Needed the cash, so I locked in the gains faster than a market maker on an earnings gap up. Who else is cashing out some wins today 🚀💸💰💰💰 The structural setup on this stock remains highly compelling, with a clear path for further price discovery. 📈🔥 The short squeeze is just beginning, meaning forced covering could amplify price acceleration as liquidity tightens. With $28 and $30 as the next 🔑🎯key levels, a breakout toward 🚀 $45 looks increasingly probable, especially if volume surges confir
$Aligos Therapeutics, Inc.(ALGS)$ 🔺🅱️ṳ̈l̤̈l̤̈ï̤s̤̈ḧ̤ 📈 $27 first 🎯 $ALGS, Momentum Shift Detected, High-Probability Reversal Setup in Play 📊🚀 📈 Key Technical Developments • VWAP Expansion & Volume Uptick: A sustained rise in VWAP alongside increasing volume suggests an influx of institutional participation, indicative of potential accumulation at current levels. This signals improving liquidity dynamics and a possible trend reversal confirmation. • Reversal Candle Emergence: The latest candlestick structure exhibits characteristics of a strong reversal formation, aligning with key technical inflection points. If confirmed, this price action implies a momentum shift favoring bullish continuation. • Successful Retest & Bounce Reaction: Price
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-ß agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH, as well as a research collaboration and development agreement with Xiamen Amoytop Biotech Co., Ltd. to research and develop oligonucleotide compounds for the treatment of liver diseases.. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
08-07
Employee Stock Ownership
Form S-8 - Securities to be offered to employees in employee benefit plans